IP Library Granted Patent US 8,728,815
Granted Patent B2
US 8,728,815 · App. 13/488,590 · Granted May 20, 2014

Induction of differential stress resistance and uses thereof

Inventor: Valter Longo (Playa del Rey, CA)
Assignee: University of Southern California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,815
App. No.
13/488,590
Granted
May 20, 2014
Kind
B2
Abstract

This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.

Claims (30)

1. A method protecting cells in a subject from a DNA damaging agent, the method comprising:

starving the subject for 24-60 hours to induce differential stress resistance in the subject; and

administering to the DNA damaging agent to the subject.

2. The method of claim 1 , wherein the subject is starved for 48 hours.

3. The method of claim 1 , wherein glucose level is reduced by 25 to 45 percent as compared to the glucose level prior to starving of the subject.

4. The method of claim 1 , wherein IGF-I level in the subject is reduced as compared to the IGF-I level prior to starving of the subject.

5. The method of claim 1 , wherein the DNA damaging agent is a DNA alkylating agent.

6. The method of claim 1 , wherein the DNA damaging agent is methyl methanesulfonate or menadione.

7. The method of claim 1 , wherein the DNA damaging agent is methyl methanesulfonate, cyclophosphamide, etoposide or doxorubicin.

8. The method of claim 1 , wherein the DNA damaging agent is etoposide or doxorubicin.

9. The method of claim 1 , wherein the subject is a cancer patient.

10. The method of claim 1 , wherein the subject is a prostate cancer patient.

11. The method of claim 1 , further comprising administering to the subject a cell growth inhibitor.

12. The method of claim 11 , wherein the cell growth inhibitor inhibits GH signaling in the subject.

13. The method of claim 11 , wherein the cell growth inhibitor is an IGFBP-1.

14. A method of protecting a cell from a DNA damaging agent, the method comprising:

starving the cell for 24-60 to induce differential stress resistance; and

contacting the cell with the DNA damaging agent.

15. The method of claim 14 , further comprising contacting the cell with a cell growth inhibitor.

16. The method of claim 15 , wherein the cell growth inhibitor is an IGFBP-I.

17. The method of claim 14 , wherein the DNA damaging agent is a DNA alkylating agent.

18. The method of claim 14 , wherein the DNA damaging agent is methyl methanesulfonate or menadione.

19. The method of claim 14 , wherein the DNA damaging agent is methyl methanesulfonate, cyclophosphamide, etoposide or doxorubicin.

20. The method of claim 14 , wherein the DNA damaging agent is etoposide or doxorubicin.

21. A method protecting cells in a subject from a DNA damaging agent, the method comprising:

starving the subject with cancer for 24-60 hours to induce differential stress resistance in the subject;

administering to the DNA damaging agent to the subject; and

monitoring the toxicity of the DNA damaging agent in the subject.

22. The method of claim 21 , wherein toxicity of the DNA damaging agent is monitored by measuring LDH levels.

23. The method of claim 21 , wherein toxicity of the DNA damaging agent is monitored by measuring weight loss in the subject.

Continuity (4)
Continuation 12058600 · Mar 28, 2008
Provisional Application 60908636 · Mar 28, 2007
Provisional Application 60942561 · Jun 7, 2007
Related Publication 20120329712A1 · Dec 27, 2012